Overview

A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas

Status:
Terminated

Trial end date:
2006-08-01

Target enrollment:

Participant gender:

Summary

Phase I will determine the MDT and evaluate the safety profile of oral lenalidomide days 1-21 and weekly gemcitabine days 1, 8, & 15 in 28 day cycles Phase II will explore the anti-tumor activity and safety of the combination in subjects with advanced pancreatic carcinoma. Subjects will receive oral lenalidomide days 1-21 and weekly gemcitabine days 1, 8, & 15 in 28 day cycles until documented disease progression occurs.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Celgene Corporation

Collaborator:

Prologue Research International

Treatments:

Gemcitabine
Lenalidomide
Pancrelipase